ANDA 203683, held by Watson Laboratories. Nebivolol Hydrochloride.
As of Nov 21, 2026, ANDA 203683 (Nebivolol Hydrochloride), held by Watson Laboratories, was first approved by FDA on Nov 27, 2015, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 27, 2015 | Original application | Approved |
| Nebivolol HydrochlorideEQ 2.5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 10MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 20MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Aug 1, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 1, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 27, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters